Sarepta Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 70 Posts
1 2 3 ... 5
5 Gene Therapy Stocks Back In Focus On AbbVie/Regenxbio Deal
Article By: Zacks Investment Research Tuesday, September 14, 2021 3:32 PM EDT
Gene therapy is set to become one of the most vital spaces with high prospects in the biotech sector.
In this article: SRPT, QURE, SLDB, MGTX, VYGR Also: ABBV, RGNX
Read
Biotech Bloodbath: Hedge Fund Hotel Sarepta Collapses After Study Disappoints
Article By: Tyler Durden Thursday, January 7, 2021 6:59 PM EDT
Sarepta, the hedge-fund-hotel has done it again, collapsing over 50% after hours following reports that a key study from the industry leader missed lofty investor expectations.
In this article: SRPT
Read
Sarepta Price Target Raised To $260 From $160 At H.C. Wainwright
Article By: The Fly Friday, December 13, 2019 8:06 AM EDT
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Sarepta Therapeutics to $260 from $160 after the FDA reversed course and approved Vyondys 53.
In this article: SRPT
Read
Biotech Scoreboard, November: Gene Therapy Stocks Gain Momentum
Article By: Rod Raynovich Saturday, November 30, 2019 11:38 PM EDT
IBB is up 11.2% for November, XBI up 6.3%, but NASDAQ-100 (QQQ) leads up 14.5 %. The big winners for the month include NTLA up 47.24%.
In this article: IBB, QQQ, XBI, SRPT, NTLA, CRSP
Read
Biotech (Top 30 Weights) 2019 Earnings Estimates Up 8.58% In Last 2 Months
Article By: T.J. Hayes Monday, September 9, 2019 7:36 PM EDT
The cumulative earnings power of these 30 stocks was revised UP by 8.58% in the past 60 days.
In this article: ALNY, ALXN, BMRN, CBPO, ILMN, INCY, JAZZ, REGN, SGEN, AMGN, BIIB, CELG, EXEL, GILD, HZNP, MYL, NBIX, TECH, VRTX, AMRN, SAGE, GWPH, SRPT, BLUE, NVCR, IONS, BGNE, PRAH, SYNH, IBB
Read
5 Monster Stocks To Watch For Wednesday, August 21
Article By: Michael J. Kramer Wednesday, August 21, 2019 4:32 AM EDT
There is the possibility we continue to drift lower on today, as the index works its way towards 2890, in an attempt to refill a gap.
In this article: AMD, JD, BAC, AMZN, SRPT Also: FXI, SPY, VXX
Read
3 Bull Stocks Driving Analysts Crazy
Article By: TipRanks Thursday, September 27, 2018 9:22 AM EDT
Take a closer look at these three stocks.
In this article: SRPT, BX, AMZN
Read
Sarepta Price Target Raised To $168 From $83 At Piper Jaffray
Article By: The Fly Wednesday, June 20, 2018 7:15 AM EDT
Piper Jaffray analyst Edward Tenthoff raised his price target for Sarepta Therapeutics to $168 from $83 after the company presented Phase I/II data on three Duchenne muscular dystrophy boys receiving its micro-dystrophin gene therapy.
In this article: SRPT
Read
Biotech Stocks Emerge Unscathed And Ready To Go
Article By: Tarun Chandra, CFA Friday, May 18, 2018 8:41 PM EDT
The biotech stocks have been demonstrating strong resilience in the face of intense volatility since February and, remarkably, keeping pace with the broader indexes, considering the highly speculative and volatile nature of the group.
In this article: CVS, MRK, IBB, INCY, ESRX, XBI, ARNA, ECYT, IMMU, IRWD, DVAX, SUPN, SRPT, AGIO, QURE, HRTX, LOXO, ATRA, BGNE, ADAP, CRSP, CBIO, GTHX, MRTX
Read
Sarepta Drops After U.K. Trial Halt, But Analysts Unconcerned
Article By: The Fly Friday, February 9, 2018 1:50 PM EDT
Shares of Sarepta Therapeutics dropped in morning trading following a report that said that the company had halted treatment at sites in the United Kingdom testing its Duchenne muscular dystrophy drug golodirsen.
In this article: SRPT Also: SLDB
Read
E Why Sarepta Therapeutics Inc Looks On Track For A Second DMD Approval
Article By: Samuel Rae Wednesday, October 11, 2017 9:36 AM EDT
Here's a look at Sarepta's latest data and where it fits into the company's Duchenne muscular dystrophy (DMD) portfolio. From a trader's perspective, Sarepta looks like it could be a strong pick heading into early 2018 and beyond.
In this article: SRPT
Read
Top Analysts Are Betting On These 5 Hot Stocks For 2018
Article By: TipRanks Sunday, October 8, 2017 3:36 PM EDT
Biopharma Sarepta Therapeutics is soaring right now, and top analysts are confident that this stock still has further room to grow. Analysts are predicting that Sarepta can climb by a further 29% over the next 12 months.
In this article: GVA, FOLD, AVGO, SRPT, JD
Read
XBI Breaks Through On A Strong Week For Biotech
Article By: Rod Raynovich Friday, September 29, 2017 7:25 PM EDT
The XBI is up 3.17% this week, 46% YTD, compared to only 1.1% WTD for the IBB. The breakthrough gains for the XBI can be attributed to strong performance of top ten holdings that are primarily mid-caps and M&A prospects.
In this article: BMY, ALNY, BMRN, IBB, AMGN, CELG, CLVS, XBI, JUNO, PBYI, SRPT, BLUE, PTCT, ABBV, FMI
Read
Sarepta Seen As 'Bargain' For Potential Big Pharma Buyer
Article By: The Fly Thursday, June 8, 2017 3:48 PM EDT
While approval for Sarepta Therapeutic's Exondys 51 in the U.S. was controversial, Oppenheimer analyst Hartaj Singh said it has resulted in a "high level" of short interest and the company would be a "bargain" if it is acquired.
In this article: SRPT Also: ALIOF, PFE, JNJ, TKPYY
Read
Biotech Bonanza – Approaching An Inflection Point
Article By: Tarun Chandra, CFA Saturday, May 6, 2017 6:42 PM EDT
Biotechs are performing well this year even in an uncertain environment. Policy clarity is important and we may be approaching an inflection point for them to push higher. Investors should maintain exposure to this volatile but promising sector.
In this article: IBB, SPY, XBI, ALXN, AMGN, BIIB, CELG, BIVV, LLY, MRK, PFE, INCY, GILD, SRPT
Read
Options Trading Week In Review
Video By: Jonathan Rose Friday, April 28, 2017 6:30 PM EDT
Options analysis, strategies, and a bit of coaching around this week's market action.
In this video: SRG, WTW, SRPT, EHTH, TUR, TTEK, AMD, FB Also: BABA, M
Watch
1 to 16 of 70 Posts
1 2 3 ... 5